Development of therapy that targets ovarian clear cell carcinoma stem cells
Project/Area Number |
24501313
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Tumor biology
|
Research Institution | Kyoto Prefectural University of Medicine (2013-2014) The University of Tokyo (2012) |
Principal Investigator |
NASU Ryo 京都府立医科大学, 医学(系)研究科(研究院), 助教 (30466859)
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | 癌 / 癌幹細胞 / 卵巣明細胞癌 / CD133 / Wntシグナル / LGR5 / デスモソーム |
Outline of Final Research Achievements |
Clear cell carcinoma of the ovary (CCC) has the worst prognosis among epithelial ovarian cancers because of its chemoresistance. In this study, we tried to develop a new therapy that targets CCC stem cells. We analyzed the gene expression profile of CCC stem cells established by our group and found the high expression of the stem cell marker LGR5. Moreover, we analyzed the molecular mechanisms of the activation of Wnt signaling by the R-spondin-LGR5 axis and found that R-spondin/Wnt stimuli activate Wnt signaling via promoting novel phosphorylation of Axin1. Thus, both antibodies that target the extracellular domain of LGR5 and small molecules that inhibit Axin1 phosphorylation hold promise as novel anti-tumor reagents.
|
Report
(4 results)
Research Products
(11 results)
-
-
-
-
[Journal Article] PCDH10 is required for the tumorigenicity of glioblastoma cells2014
Author(s)
Kanae Echizen, Mitsutoshi Nakada , Tomoatsu Hayashi, Hemragul Sabit, Takuya Furuta, Miyuki Nakai, Ryo Koyama-Nasu, Yukiko Nishimura, Kenzui Taniue, Yasuyuki Morishita, Shinji Hirano, Kenta Terai, Tomoki Todo, Yasushi Ino, Akitake Mukasa, Shunsaku Takayanagi, Ryohei Ohtani, Nobuhito Saito, Tetsu Akiyama
-
Journal Title
Biochem. Biophys. Res. Commun.
Volume: 444
Issue: 1
Pages: 13-18
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] The pleiotrophin-ALK axis is required for tumorigenicity of glioblastoma stem cells2013
Author(s)
R Koyama-Nasu, R Haruta, Y Nasu-Nishimura, K Taniue, Y Katou, K Shirahige, T Todo, Y Ino, A Mukasa, N Saito, M Matsui, R Takahashi, A Hoshino-Okubo, H Sugano, E Manabe, K Funato and T Akiyam
-
Journal Title
Oncogene
Volume: 33
Issue: 17
Pages: 2236-2244
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] The cancer stem cell marker CD133 interacts with plakoglobin and controls desmoglein-2 protein levels.2013
Author(s)
Koyama-Nasu R, Takahashi R, Yanagida S, Nasu-Nishimura Y, Oyama M, Kozuka-Hata H, Haruta R, Manabe E, Hoshino-Okubo A, Omi H, Yanaihara N, Okamoto A, Tanaka T, and Akiyama T.
-
Journal Title
PLoS One
Volume: 8
Issue: 1
Pages: e53710-e53710
DOI
Related Report
Peer Reviewed
-
[Journal Article] The critical role of cyclin D2 in cell cycle progression and tumorigenicity of glioblastoma stem cells2013
Author(s)
R Koyama-Nasu, Y Nasu-Nishimura, T Todo, Y Ino, N Saito, H Aburatani, K Funato, K Echizen, H Sugano, R Haruta, M Matsui, R Takahashi, E Manabe, T Oda and T Akiyama
-
Journal Title
Oncogene
Volume: 32
Issue: 33
Pages: 3840-3845
DOI
Related Report
Peer Reviewed
-
-
-
-